Physician
Hematology
Dr. Marc R. Theoret, MD
|
|
Give Review
Marc R. Theoret, MD is an expert in the field of Hematology. He graduated from Penn State College of Medicine. Marc Theoret is a published doctor and has 20 publications published. The lastest was: 'FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation.'
Publications
- FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation.
- The risks and benefits of 5?-reductase inhibitors for prostate-cancer prevention.
- Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials.
- Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.
- Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.
- Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells.
- TSCOT+ thymic epithelial cell-mediated sensitive CD4 tolerance by direct presentation.
- Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer.
- CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.
- Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.
- Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.
- Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
- Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance.
- IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
- High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition...
- Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
- Assumptions of the tumor 'escape' hypothesis.
- The future of interleukin-2: enhancing therapeutic anticancer vaccines.
- Cross-priming utilizes antigen not available to the direct presentation pathway.
Schools
Pennsylvania State University College of Medicine
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Education
-
National Institutes of Health Clinical Center -
Beth Israel Deaconess Medical Center -
Penn State College of Medicine